Kožní ordinace

The Kožní ordinace is conducting a study to assess the benefit of sonelokimab in adults with moderate to severe hidradenitis suppurativa, an immune‑mediated skin condition. The trial compares the drug to placebo to determine its impact on disease clearance over a 16‑week period.

• Evaluation of sonelokimab efficacy in hidradenitis suppurativa
• Placebo‑controlled assessment of HiSCR75 response
• Investigation of immune modulation in skin inflammation

This research highlights the site’s commitment to advancing therapies for immune‑driven dermatologic disorders.

A parallel investigation at the Prague clinic examines a proposed biosimilar, JPB898, to the established immunotherapy drug nivolumab in patients with advanced (unresectable/metastatic) melanoma. The study evaluates pharmacokinetic similarity, safety, and combined use with ipilimumab.

• Biosimilarity testing of JPB898 to Opdivo®
• Combination therapy with nivolumab and Yervoy®
• Pharmacokinetic and immunogenicity profiling in metastatic melanoma

These efforts aim to expand treatment options for patients facing aggressive skin‑origin cancers.

The research program at Kožní ordinace encompasses a broad range of skin‑related conditions, integrating trials on both inflammatory disorders like hidradenitis suppurativa and malignant diseases such as melanoma. Emphasis is placed on novel biologic delivery and patient‑centered outcome measures.

• Subcutaneous administration strategies for dermatologic biologics
• Safety monitoring and adverse event reporting in skin trials
• Use of patient‑reported outcomes to gauge treatment impact

By addressing diverse skin pathologies, the site supports innovative solutions for connective tissue health.